Latest Multiple myeloma Stories
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors.
“Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma” and “Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02
TG02 synergizes with carfilzomib in multiple myeloma models; data to be presented at ASH 2013 Annual Meeting. San Diego (PRWEB) December 03, 2013 Tragara
In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).